Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: A single center experience

Pituitary

Volumn 15, Issue 1, 2012, Pages 25-29

  Anagnostis, Panagiotis ^a   Adamidou, Fotini ^a   Polyzos, Stergios A ^a   Efstathiadou, Zoe ^a   Karathanassi, Eleni ^a   Kita, Marina ^a  

^a Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Bromocriptine; Cabergoline; Dopamine agonists; Hyperprolactinemia; Prolactinomas; Quinagolide

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; MACROADENOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROADENOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REMISSION; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; BROMOCRIPTINE; DOPAMINE AGONISTS; ERGOLINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROLACTINOMA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858142850     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0303-6     Document Type: Article

References (21)

1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273 (Pubitemid 44079693)
2. Kars M, Dekkers OM, Pereira AM, Romijn JA (2010) Update in prolactinomas. Neth J Med 68:104-112
3. Acquati S, Pizzocaro A, Tomei G, Giovanelli M, Libè R, Faglia G, Ambrosi B (2001) A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurosurg Sci 45:65-69 (Pubitemid 32979938)
4. Nomikos P, Buchfelder M, Fahbusch R (2001) Current management of prolactinomas. J Neurooncol 54:139-150 (Pubitemid 33089247)
5. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518-2522
6. Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428-2436
7. Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22:354-359 (Pubitemid 29259557)
8. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579 (Pubitemid 27509339)
9. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet 2:187-192 (Pubitemid 14094955)
10. Maxson WS, Dudzinski M, Handwerger SH, Hammond CB (1984) Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil Steril 41:218-223 (Pubitemid 14169506)
11. van 't Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175-178
12. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537-546 (Pubitemid 28014506)
13. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126: 489-494
14. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26-31 (Pubitemid 40966398)
15. Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Longterm follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578-3582 (Pubitemid 34879499)
16. Rasmussen C, Bergh T, Wide L (1987) Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertil Steril 48:550-554 (Pubitemid 17154403)
17. Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 72:507-511
18. Colao A, Di Sarno A, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-2033 (Pubitemid 37448925)
19. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67:426-433 (Pubitemid 47283843)
20. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and metaanalysis. J Clin Endocrinol Metab 95:43-51
21. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53:53-60 (Pubitemid 30646126)